Cleveland Clinic Study Shows Less Weight Regain After Stopping Ozempic and Wegovy Than Expected

Recent research from Cleveland Clinic is challenging what many people thought they knew about stopping weight loss medications like Ozempic and Wegovy. A new study published in the journal Diabetes, Obesity and Metabolism analyzed nearly eight thousand patients who used semaglutide or tirzepatide for three to twelve months before discontinuing treatment. The findings offer surprising hope compared to earlier clinical trials that suggested dramatic weight regain after stopping these drugs.

In the real world, patients who stopped taking these medications regained far less weight than researchers expected. Among those treated specifically for obesity, the average weight loss before stopping was eight point four percent. One year later, they had regained just half a percent on average. The key difference between this study and previous clinical trials comes down to what happens after patients stop. In real world settings, patients have more options. According to lead researcher Dr. Hamlet Gasoyan from Cleveland Clinic, many patients who stop taking semaglutide or tirzepatide restart the medication or transition to another obesity treatment, which explains why they regain less weight than patients in randomized trials.

The research found that about twenty seven percent of patients switched to different medications including older generation obesity drugs, while another twenty percent eventually restarted their original medication once insurance issues or side effects were resolved. Another fourteen percent moved to intensive lifestyle modification programs working with dietitians and exercise specialists. This ongoing engagement with healthcare support appears to be the crucial factor in maintaining weight loss.

The findings have resonated with high profile discussions about these medications. Media mogul Oprah Winfrey recently addressed viral speculation about her weight loss after appearing at Paris Fashion Week in early March. While some online observers speculated about her use of GLP-1 medications, Oprah clarified that her careful walk into the venue was simply because she could not see clearly without her glasses or contacts. However, Oprah previously disclosed in a December 2023 interview that she does use weight management medication and described it as feeling like relief and redemption. When she briefly stopped taking the medication less than six months after starting, she gained about twenty pounds over twelve months despite maintaining a healthy diet and exercise routine. This experience convinced her that the medication may be necessary long term, and she has stated it will likely be a lifetime commitment for her.

The Cleveland Clinic study suggests that the dramatic weight rebound seen in controlled clinical trials may not reflect what actually happens in everyday medical practice. When patients maintain connection with healthcare providers through alternative treatments or structured support, they can successfully manage their weight even after stopping their initial medication. This real world evidence provides an encouraging perspective for the millions of people currently using these popular weight loss drugs.

Thanks for listening, please subscribe, and remember this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai.

Some great Deals https://amzn.to/49SJ3Qs

For more check out http://www.quietplease.ai

This content was created in partnership and with the help of Artificial Intelligence AI